Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 11/20 | 0.67 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.54 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.54 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.52 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.52 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27580357 | 0.88 | ADK (0.66) | ADKPRMT5WDR77DOT1LPRMT3 | |
| SCHEMBL6876234 | 0.87 | ADK (0.73) | ADKPRMT5WDR77DOT1LPRMT3 | |
| SCHEMBL6879012 | 0.87 | ADK (0.73) | ADKPRMT5WDR77DOT1LPRMT3 | |
| SCHEMBL6877858 | 0.84 | ADK (0.69) | ADKPRMT5WDR77DOT1LPRMT3 | |
| SCHEMBL6877859 | 0.84 | ADK (0.69) | ADKPRMT5WDR77DOT1LPRMT3 | |
| SCHEMBL6878980 | 0.84 | ADK (0.69) | ADKPRMT5WDR77DOT1LPRMT3 | |
| SCHEMBL6878975 | 0.84 | ADK (0.69) | ADKPRMT5WDR77DOT1LPRMT3 | |
| SCHEMBL6879492 | 0.82 | ADK (0.63) | ADKPRMT5WDR77DOT1LPRMT3 | |
| SCHEMBL6877410 | 0.80 | ADK (1.00) | ADKPRMT5DOT1LPRMT3DNMT1 | |
| SCHEMBL3882863 | 0.80 | PRMT5 (0.49) | ADKPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831069-B2 | Having substituents at the C4' and C5' positions of the ribofuranose moiety; anticancer and immunomodulating effects at reduced cytotoxicity; treating autoimmune diseases, cancer, dermatitis | RIBAPHARM INC. | 2004-12-14 | — | — | US | disclosed |
| US-20020035077-A1 | Pyrrolo[2,3-d]pyrimidine nucleoside analogs | CEQUENT PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035077-A1 | Pyrrolo[2,3-d]pyrimidine nucleoside analogs | TYMP, DPYD, TYMS | ADK 662/4885PRMT5 864/4885WDR77 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.